Novo Nordisk A/S, Brennum Park, DK-3400 Hillerød, Denmark.
Expert Opin Drug Deliv. 2011 Oct;8(10):1271-6. doi: 10.1517/17425247.2011.615308. Epub 2011 Sep 2.
FlexTouch® (FT) (Novo Nordisk A/S, Bagsværd, Denmark) is a new prefilled insulin pen with a novel injection mechanism encompassing no push-button extension at any dose-setting. This study assessed the dose accuracy and injection force of FT compared with the established Next Generation FlexPen® (NGFP) (Novo Nordisk A/S Bagsværd, Denmark).
Dose accuracy was measured at the minimum, medium and maximum doses (FT, 1, 40 and 80 international units (IU) and NGFP, 1, 30 and 60 IU). Injection force was measured during the injection of the maximum dose (FT, 80 IU; NGFP, 60 IU).
FT and NGFP delivered insulin accurately and consistently at all doses (mean ± s.d., FT at 1 IU, 0.98 ± 0.07; 40 IU, 39.86 ± 0.33; 80 IU, 79.76 ± 0.64; NGFP at 1 IU, 1.02 ± 0.08; 30 IU, 29.69 ± 0.30; 60 IU, 59.50 ± 0.51). FT had a significantly (p < 0.0001) lower injection force than NGFP.
The study demonstrated that FT and NGFP deliver insulin accurately and consistently at low, medium and high doses. The novel torque spring injection mechanism of FT results in a significantly lower injection force than NGFP and a pen requiring less thumb-pressure to inject insulin may be welcomed by many people with diabetes.
FlexTouch®（FT）（丹麦诺和诺德公司）是一种新型预填充胰岛素笔，其新型注射机构在任何剂量设置时都没有推键延伸。本研究评估了 FT 与已确立的下一代 FlexPen®（NGFP）（丹麦诺和诺德公司）在剂量准确性和注射力方面的差异。
在最小、中、最大剂量（FT：1、40 和 80 国际单位（IU）和 NGFP：1、30 和 60 IU）下测量剂量准确性。在最大剂量（FT：80 IU；NGFP：60 IU）注射过程中测量注射力。
FT 和 NGFP 在所有剂量下均能准确、一致地输送胰岛素（平均值±标准差，FT 在 1 IU 时为 0.98±0.07；40 IU 时为 39.86±0.33；80 IU 时为 79.76±0.64；NGFP 在 1 IU 时为 1.02±0.08；30 IU 时为 29.69±0.30；60 IU 时为 59.50±0.51）。FT 的注射力明显低于 NGFP（p<0.0001）。
该研究表明，FT 和 NGFP 在低、中、高剂量下均能准确、一致地输送胰岛素。FT 的新型扭矩弹簧注射机构可显著降低注射力，对于许多糖尿病患者而言，使用需要施加较小拇指压力即可注射胰岛素的笔可能会受到欢迎。
